INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more
INVEX Therapeutics Ltd (IXC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.171x
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has a cash flow conversion efficiency ratio of -0.171x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-779.73K) by net assets (AU$4.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
INVEX Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
INVEX Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INVEX Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FalconStor Software Inc
PINK:FALC
|
-2.162x |
|
Prophecy International Holdings Ltd
AU:PRO
|
-2.309x |
|
Bangun Karya Perkasa Jaya
JK:KRYA
|
-0.886x |
|
ImagineAR Inc
OTCQB:IPNFF
|
0.046x |
|
Sygnia Ltd
JSE:SYG
|
0.363x |
|
Smart Powerr Corp
NASDAQ:CREG
|
0.000x |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
N/A |
|
Audeara Ltd
AU:AUA
|
0.024x |
Annual Cash Flow Conversion Efficiency for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of INVEX Therapeutics Ltd from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.25 Million | AU$-652.57K | -0.124x | +71.05% |
| 2024-06-30 | AU$5.69 Million | AU$-2.44 Million | -0.430x | -32.80% |
| 2023-06-30 | AU$21.23 Million | AU$-6.87 Million | -0.324x | -172.89% |
| 2022-06-30 | AU$28.48 Million | AU$-3.38 Million | -0.119x | -126.62% |
| 2021-06-30 | AU$32.08 Million | AU$-1.68 Million | -0.052x | +20.38% |
| 2020-06-30 | AU$24.40 Million | AU$-1.60 Million | -0.066x | -226.59% |
| 2019-06-30 | AU$11.44 Million | AU$-230.13K | -0.020x | -- |